HYPOTHESIS AND THEORY article
Front. Oncol.
Sec. Cancer Immunity and Immunotherapy
This article is part of the Research TopicCell fusion and immune regulation in cancer and tissue regeneration: Emerging paradigms and therapeutic implicationsView all articles
The authors respond to feedback on Cancer Cell-Memory Macrophage Hybrid Theory for metastatic cancer cells
Provisionally accepted- 1Shanghai Institute of Nutrition and Health, Chinese Academy of Sciences (CAS), Shanghai, China
- 2Shanghai University, Shanghai, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
We have recently hypothesized that the hematogenous metastatic cancer cell of solid tumors is a hybrid between a primary cancer cell and a memory/trained macrophage (doi: 10.3389/fonc.2024.1412296). The hybrid cell respectively acquires mutator phenotype and overgrowth/hyperplasia property from the primary cancer cell and migratability/metastability from the memory/trained macrophage. We name this hypothesis Cancer Cell-Memory Macrophage Hybrid Theory. Since the publication of the article, a number of questions related to this Theory have been raised by colleagues in the oncology community, including intratumoral microbes and microbiomes/microbiotas, oncolytic viruses and bacteria, and human papilloma virus vaccines, anti-cancer effects of γδ T-cells, immune checkpoint inhibitors. The current article is prepared to address these issues. Additional to resolve questions like "Why metastatic cancer cells enter dormancy and can recur via stem-like self-renewal?", the Cancer Cell-Memory Macrophage Hybrid Theory distinguishes itself from other carcinogenesis and metastasis hypotheses/theories by offering answers to many puzzling clinical features including metastasis of seemingly malignant parasitic cells within the human body, intracellular microbes (including viruses, bacteria, fungi, and parasites) within cancer cells, paradoxal effects (recurrence vs. regression) of microbes on cancer, contradictory immune effects of human papilloma virus between young and adult/senior females, and immune context-dependent effects (stimulatory and inhibitory) of T-lymphocytes on cancer cells. The Theory also predicts that quantitatively and functionally dampening innate macrophages that have hybridized with cancer cells (i.e., cancer cell-memory macrophage hybrids), should be explored as a fundamental anti-cancer strategy. The Theory further forecasts how to prepare an organotropic/tumoritropic Coley's toxin-like anti-cancer microbe, which could potentially circumvent direct injection of these microbial preparations into a tumor. A testable experiment that uses zebrafish larva models can potentially either validate or falsify the Theory.
Keywords: Coley's toxin, human papilloma virus vaccine/HPV vaccine, Immune checkpoint inhibitor, intratumoral bacterium/intratumoral microbe/intratumoral microbiome/intratumoral microbiota, metastasis, oncolytic virus/oncolytic bacterium, trained macrophage/memory macrophage, tumor hybrid cell
Received: 04 Jan 2026; Accepted: 16 Feb 2026.
Copyright: © 2026 Wu and Jiang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Jiaxi Wu
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
